

PP38

IS SALVAGE FOCAL CRYOTHERAPY CURATIVE TREATMENT FOR PATIENTS WITH LOCALIZED RECURRENT PROSTATE CANCER?

C. J. Berg, K. E. Kosinski, A. E. Katz

Winthrop University Hospital, Mineola, NY 11501, USA

Introduction and Objective: The salvage therapy options for patients with recurrent unilateral prostate cancer after primary radiation, or cryotherapy are limited. Salvage focal cryotherapy is becoming a more popular treatment option as it has shown success in its disease free survival rates. Salvage focal cryotherapy enables patients to delay or negate the use of hormone therapy which has many unfavorable adverse effects. The aim of this study is to report on the curative success of salvage focal cryotherapy in recurrent unilateral prostate cancer patients.

Methods: We identified patients that underwent salvage focal cryotherapy at Winthrop University Hospital between February 2011 and August 2015. Age at the time of treatment, follow up time, nadir PSA levels and follow up treatments were assessed.

Results: From 2011 to 2015, 88 patients underwent salvage focal cryoablation. Of these patients, 14 (15.9%) required another therapy treatment after salvage focal cryoablation. Hormone therapy was a necessary treatment for 9 patients. Only 6 patients (6.8%) went on to hormone therapy due to an MRI finding of a local, nodal, or distant relapses. Three (3.4%) patients went on to hormone therapy due to a rise in PSA.

Table I. Patient Characteristics	
Variables	N=88
Age, mean (range), year	71 (53-86)
Follow up time, median (range), months	15 (0-74)
Nadir PSA, median (range), ng/ml	0.53 (0.01-66.4)
Treatments following Salvage	
Hormones	9
Focal Salvage	4
Total Salvage	1
Time to Hormones Median (range), months	9 (4-20)
Cause for Hormone Therapy	
Rise in PSA	3
Local relapse	2
Nodal Relapse	3
Distant Relapse	1

Conclusions: Focal salvage therapy is associated with very low risk of clinical and radiographic progression of cancer. In our patients with radiation recurrent cancer we were able to prevent or delay the use of hormone therapy in the majority of these men.